Lyell Immunopharma Stock Total Debt
| LYEL Stock | USD 0.92 0.01 1.10% |
Lyell Immunopharma fundamentals help investors to digest information that contributes to Lyell Immunopharma's financial success or failures. It also enables traders to predict the movement of Lyell Stock. The fundamental analysis module provides a way to measure Lyell Immunopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lyell Immunopharma stock.
The value of Total Debt To Capitalization is expected to slide to 0.06. Lyell | Total Debt |
Lyell Immunopharma Company Total Debt Analysis
Lyell Immunopharma's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Lyell Immunopharma Total Debt | 63.17 M |
Most of Lyell Immunopharma's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lyell Immunopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lyell Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Lyell Immunopharma is extremely important. It helps to project a fair market value of Lyell Stock properly, considering its historical fundamentals such as Total Debt. Since Lyell Immunopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lyell Immunopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lyell Immunopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Lyell Total Debt Historical Pattern
Today, most investors in Lyell Immunopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lyell Immunopharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Lyell Immunopharma total debt as a starting point in their analysis.
Lyell Immunopharma Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Lyell Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Lyell Immunopharma has a Total Debt of 63.17 M. This is 97.7% lower than that of the Biotechnology sector and 80.55% lower than that of the Health Care industry. The total debt for all United States stocks is 98.81% higher than that of the company.
Lyell Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lyell Immunopharma's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lyell Immunopharma could also be used in its relative valuation, which is a method of valuing Lyell Immunopharma by comparing valuation metrics of similar companies.Lyell Immunopharma is currently under evaluation in total debt category among its peers.
Lyell Immunopharma Institutional Holders
Institutional Holdings refers to the ownership stake in Lyell Immunopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lyell Immunopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lyell Immunopharma's value.| Shares | Sc China Holding Ltd | 2024-09-30 | 3 M | Mic Capital Management Uk Llp | 2024-09-30 | 1.7 M | Opaleye Management Inc | 2024-09-30 | 1.4 M | Northern Trust Corp | 2024-09-30 | 1.4 M | Balyasny Asset Management Llc | 2024-09-30 | 1.2 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.1 M | Fmr Inc | 2024-09-30 | 1 M | Td Asset Management Inc | 2024-09-30 | 1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 901.5 K | Mwg Management Ltd. | 2024-06-30 | 20.2 M | Orland Properties Ltd | 2024-06-30 | 15.1 M |
Lyell Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | (132.08 M) | ||||
| Shares Outstanding | 279.22 M | ||||
| Shares Owned By Insiders | 14.06 % | ||||
| Shares Owned By Institutions | 61.64 % | ||||
| Number Of Shares Shorted | 9.6 M | ||||
| Price To Earning | 3.66 X | ||||
| Price To Book | 0.48 X | ||||
| Price To Sales | 4,080 X | ||||
| Revenue | 130 K | ||||
| Gross Profit | 84.68 M | ||||
| EBITDA | (226.76 M) | ||||
| Net Income | (234.63 M) | ||||
| Cash And Equivalents | 655.56 M | ||||
| Cash Per Share | 2.64 X | ||||
| Total Debt | 63.17 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 13.26 X | ||||
| Book Value Per Share | 2.07 X | ||||
| Cash Flow From Operations | (163.69 M) | ||||
| Short Ratio | 5.18 X | ||||
| Earnings Per Share | (0.79) X | ||||
| Price To Earnings To Growth | 0.68 X | ||||
| Target Price | 2.0 | ||||
| Number Of Employees | 224 | ||||
| Beta | -0.48 | ||||
| Market Capitalization | 257.02 M | ||||
| Total Asset | 750.03 M | ||||
| Retained Earnings | (1 B) | ||||
| Working Capital | 520.17 M | ||||
| Net Asset | 750.03 M |
About Lyell Immunopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lyell Immunopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lyell Immunopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lyell Immunopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Lyell Immunopharma Piotroski F Score and Lyell Immunopharma Altman Z Score analysis. For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.79) | Quarterly Revenue Growth 0.36 | Return On Assets (0.19) | Return On Equity (0.33) |
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.